Generic Name: panitumumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Amgen

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Vectibix is an EGFR inhibitor approved for treatment of metastatic colorectal cancer without RAS mutations.

General Info

Vectibix is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR), which is overexpressed in colorectal cancer and plays a role in cell growth and development of blood vessels that feed tumors.

Clinical trials showed that Vectibix delays disease progression and improves survival in people with EGFR-expressing colorectal cancer without NRAS or KRAS mutations; it is not indicated for those with RAS mutations or whose RAS status is unknown. It was first approved in 2006.


Dosing Info:

Vectibix is given by intravenous infusion. It may be used alone or in combination with chemotherapy.

Side Effects

Common side effects include skin rash, nail changes, fatigue, nausea and diarrhea. Potential serious side effects may include infusion reactions, lung and eye problems and metabolic abnormalities. It may increase tumor progression in people with RAS mutations. The Vectibix label includes a warning about severe skin reactions. Vectibix may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 16, 2018